Maximum quantity allowed is 999
Please select the quantity
CAS RN: 41859-67-0 | Product Number: B3346
Bezafibrate
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 5G |
$109.00
|
8 | 33 | Contact Us | |
| 25G |
$350.00
|
5 | 8 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | B3346 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__9H__2__0ClNO__4 = 361.82 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 41859-67-0 |
| Reaxys Registry Number | 4267656 |
| PubChem Substance ID | 87560846 |
| Merck Index (14) | 1195 |
| MDL Number | MFCD00078970 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 182.0 to 186.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 184 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | UE8755000 |
Transport Information:
| H.S.code* | 2924.29-000 |
Application
Bezafibrate: Antilipemic with Activity against Peroxisome Proliferator-Activated Receptors (PPARs)
The fibrates, including bezafibrate, clofibrate [C0941], clinofibrate [C3100] and fenofibrate [F0674] are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. The precise mechanisms of action remain unknown, but it has been reported that the major modes of action of the fibrates as follows: VLDL catabolism by increased lipoprotein and hepatic triglyceride lipase activities; suppression of triglyceride biosynthesis by acetyl-CoA carboxylase enzyme inhibition and attenuation of cholesterol biosynthesis by inhibition of the rate-limiting HMG-CoA reductase.
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)
References
- Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects
- Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolaemia
- Bezafibrate: An update of its pharmacology and use in the management of dyslipidemia (a review)
- Mechanism of action of fibrates on lipid and lipoprotein metabolism (a review)
- Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons (a review)
- Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? (a review)
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.